Transforming ALK-positive cancer through expert guidance
ALK Positive was founded on the belief that innovative, cutting-edge research is key to improving patient outcomes and ultimately transforming ALK-positive cancer into a curable disease.
Scientific Advisory Board
Our Scientific Advisory Board (SAB), comprised of renowned experts in ALK-positive cancers, guides our research initiatives and strategic direction, reinforcing our commitment to funding the highest quality research and educational programs for our patient community.
Dr. Mark Awad
Chief of the Thoracic Oncology Service within the Solid Tumor Oncology Division, Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK)
Dr. Ross Camidge
Professor of Medicine/Oncology, Joyce Zeff Chair in Lung Cancer Director, Thoracic Oncology, Faculty, Developmental Therapeutics Program, University of Colorado Cancer Center
Dr. David Carbone
Professor of Internal Medicine, Director of the James Thoracic Oncology Center at the Ohio State University Comprehensive Cancer Center, and holds the Barbara J. Bonner Chair in Lung Research
Dr. Shirish Gadgeel
Chief, Division of Hematology and Oncology, Department of Internal Medicine, Henry Ford Cancer Institute/Henry Ford Health System
Dr. John Heymach
Chair of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center and holds the David Bruton Endowed Chair in Cancer Research
Dr. Vincent Lam
Director, Thoracic Oncology Clinical Research Program, Johns Hopkins Cancer Center; Associate Professor of Oncology
Dr. Jessica Lin
Associate Professor of Medicine, Harvard Medical School, Attending Physician, Center for Thoracic Cancers and Henri and Belinda Termeer Center for Targeted Therapies, Massachusetts General Hospital
Dr. Christine Lovly
Associate Professor of Medicine, Division of Hematology-Oncology Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center
Dr. Ignatius Ou
Clinical Professor, Division of Hematology/Oncology, University of California-Irvine School of Medicine, Hamoui Salous Endowed Chair in Thoracic Oncology Research
Dr. Angel Qin
Clinical Associate Professor, Rogel Cancer Center, University of Michigan
Dr. Alice Shaw
Chief of Strategic Partnerships at Dana Farber Cancer Institute
Dr. Alex Spira
Co-Director, VCS Research Institute, Director, Thoracic and Phase I Program; Clinical Assistant Professor, Johns Hopkins. Director, Virginia Cancer Specialists (VCS) Research Institute and the Phase I Trial Program
Questions about the SAB?
Kenneth W. Culver, M. D.
Director of Research and Clinical Affairs, ALK Positive, INC.
Contact Dr. Culver at: ken.culver@alkpositive.org